Predictors of Small Intestinal Bacterial Overgrowth in Symptomatic Patients Referred for Breath Testing

Jeremy Liu Chen Kiowa, Ratiba Bellilaa, Amelie Therrien, Sacha Sidania, Mickael Bouina

Abstract

Background: Indications for a breath test (BT) are well established in the symptomatic patient with risk factors predisposing them to small intestinal bacterial overgrowth (SIBO). Characteristics and the profile of this population are not well known. Our objective was to study the characteristics of patients undergoing a BT for SIBO and to identify factors associated with a positive BT.

Methods: Retrospective study was conducted from 2012 to 2016 at the neurogastroenterology unit of the Centre Hospitalier de l’Université de Montréal (CHUM). All patients who completed a BT (lactulose and/or glucose) were included. Demographics and clinical factors were analyzed to identify predictors of positive BT. Type of antibiotic treatment and clinical response were compiled. Groups of patients with (SIBO+) and without SIBO (SIBO−) were also compared.

Results: A total of 136 patients were included in the study (mean age 51.2, range 20 - 80 years; 63% women), and SIBO was detected in 33.8% (n = 46). Both groups were similar in terms of age, body mass index, and gender. SIBO was significantly associated with the presence of abdominal pain (odds ratio (OR) = 4.78; P < 0.05), bloating (OR = 5.39; P < 0.05), smoking (OR = 6.66; P < 0.05), and anemia (OR = 4.08; P < 0.05). No association was identified with gender, age, obesity, and risk factors for SIBO. Antibiotics were used in 43% of patients with (SIBO+) and without SIBO (SIBO−) were also compared.

Conclusions: The prevalence of SIBO is high in symptomatic patients who underwent breath testing. Abdominal pain, bloating, smoking, and anemia are strongly associated with SIBO. Treatment of SIBO with antibiotics needs to be further investigated to better determine its efficacy on gastrointestinal symptoms.

Keywords: Small intestinal bacterial overgrowth; Breath test; Gastrointestinal symptoms; Predictors; Antibiotics

Introduction

Small intestinal bacterial overgrowth (SIBO) is a condition in which colonic bacteria are seen in excess (> 10^5 colony-forming units (CFU)/mL) in the small intestine causing inflammation and malabsorption [1, 2]. SIBO, sometimes asymptomatic, usually presents with symptoms of bloating, flatulence, abdominal pain, diarrhea, fatigue, and vitamin deficiencies [3]. Several conditions predispose to SIBO including intestinal stasis due to altered anatomy (abdominal surgeries, fistulas, stenoses), decreased bacterial protection mechanisms (exocrine pancreatic insufficiency, achlorhydria) and functional intestinal stasis (dysmotility in numerous chronic diseases). SIBO is therefore associated with multiple conditions such as scleroderma, irritable bowel syndrome, inflammatory bowel diseases, chronic pancreatitis, celiac disease and cirrhosis due to multiple etiologies: alcohol, viruses, primary biliary cholangitis [3-16]. It can also be present in older individuals without any underlying condition [3].

Culture of jejunal aspirates has long been considered the gold standard in diagnosing SIBO, but it is an invasive technique and is not routinely available. Breath tests (BTs), however, are non-invasive and validated for the diagnosis of SIBO [17-19]. Indications for a BT, whether it is a lactulose breath test (LBT) or glucose breath test (GBT), are well established in the symptomatic patient with risk factors predisposing them to SIBO. However, the characteristics and profile of this population are not well known. Although antibiotics are the mainstay of therapy for SIBO, the choice, dosage, and duration of antibiotic therapy are not standardized [3].

Being a reference center for digestive motility in the province of Quebec, our main objective was to study the characteristics of patients undergoing a BT for SIBO and to identify certain clinical and paraclinical factors associated with a positive BT. The clinical response to antibiotic therapy in SIBO was also assessed.

Patients and Methods

This retrospective single center study was conducted in the
Department of Gastroenterology of the Centre Hospitalier de l’Universite de Montreal (CHUM) in Montreal, Quebec, Canada. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Ethics Committee of our institution.

**Carbohydrate BT and SIBO diagnosis**

Assessment for the presence or absence of SIBO was carried out using a BT, LBT and/or GBT. Both are simple, affordable, non-invasive, standardized, and validated methods for measuring the orocecal intestinal transit and in turn the detection of SIBO [17-19].

A BT was done in patients with a clinical suspicion of SIBO and presenting non-specific gastrointestinal symptoms such as bloating, abdominal pain and diarrhea. All participants had their basal hydrogen and methane level in breath measured and expressed in part per million (ppm) using the Quintron 12i Microlyser Plus system (Milwaukee, WI, USA). Then, depending on the BT chosen by the referring physician, they ingested either 10 g of lactulose for the LBT or 75g of glucose for the GBT and had both hydrogen and methane in breath measured every 15 min for a total duration of 3 h.

Lactulose, once ingested, is not digested by the enzymes in the intestine and is fermented by colonic bacteria once it reaches the cecum, producing a hydrogen and/or methane peak that can be measured in breath [20]. The hydrogen or methane molecule passes through the blood by diffusion and then into the exhaled air, where it can be measured. The time required for a peak in hydrogen production to occur represents orocecal transit time, normally between 2 and 3 h. In the presence of SIBO, lactulose is fermented earlier (before 90 min after ingestion) in the small intestine instead of the cecum, giving rise to an earlier peak in hydrogen or methane production [21]. Glucose is absorbed in the proximal part of the small intestine. Similar to the LBT, a peak in hydrogen or methane in breath is suggestive of SIBO [21].

Data were collected and the presence of SIBO was determined if a peak in hydrogen or methane production occurred earlier than 90 min. A peak was defined as an increase in the level of hydrogen of more than 20 ppm above the basal level and 10 ppm for methane [1, 21]. The interpretation of each BT and the diagnosis of SIBO were done by gastroenterologists of our institution with expertise in neurogastroenterology and digestive motility. Patients were then classified into two separate groups: one with a BT consistent with SIBO and one with BT not consistent with SIBO.

After breath testing, all patients were then referred to their physician who decided whether or not treatment was clinically indicated. Choice of antibiotic regimen, if appropriate, was left to the discretion of the treating physician.

**Patients**

To be included in the study, patients had to be referred to the neurogastroenterology and motility unit for a BT between June 2012 and June 2016. Patients who did not undergo breath testing after referral were excluded from the study.

**Data collection**

Medical charts were carefully reviewed in order to collect relevant clinical and paraclinical data. All of the following data were collected: age, gender, body mass index (BMI), presence of gastrointestinal symptoms (such as abdominal pain, diarrhea, and bloating), presence of associated comorbidities (such as celiac disease, scleroderma, pancreatitis, cirrhosis, anemia), habits (smoking and alcohol consumption), proton pump inhibitor (PPI) use, antibiotic treatment for SIBO, and clinical response to antibiotic treatment for SIBO. No physical or paraclinical exam was performed to complete the missing data. Missing data were noted as incomplete.

**Statistical analysis**

A descriptive statistical analysis of all the collected data was performed as well as an analysis of variance (ANOVA) to test the associations of quantitative variables such as age, weight, and BMI with positive BT by comparing the characteristics of the study sample in both positive and negative BT subgroups. Thereafter, a univariate and multivariate logistic regression analysis was completed to examine the association of the predictor variables and positive BT. Predictor variables were age, gender, BMI, smoking, gastrointestinal symptoms, comorbidities associated with SIBO, and PPI intake. Statistical calculations were done with SPSS [22]. A P value of < 0.05 was used to define statistical significance in the final models.

**Results**

**Clinical characteristics and prevalence of SIBO**

Out of 150 patients who were referred to the neurogastroenterology and motility unit for breath testing, 136 patients were included in the study (mean age 51.2, range 20 - 80 years). The patients who finally refused to undergo breath testing or who did not comply with instructions were excluded from the study. The prevalence of SIBO in the patients who underwent breath testing was 33.8%, 46 BT out of 136 that were compatible with SIBO. Fourteen patients were excluded because they did not undergo breath testing after being referred. Baseline characteristics are presented in Table 1. The SIBO group was similar to the group without SIBO in terms of age (mean age 52.7, range 20 - 80 vs. 50.49, range 23 - 78 years; P = non-significant (NS)), BMI (24.88, range 17.58 - 33.33 vs. 25.41, range 14.53 - 52.47 kg/m²; P = NS) and gender (63% women in both cases, P = NS).

**Associations between SIBO (positive BT) and clinical factors**

From the clinical characteristics of patients, a significant asso-
Association was observed by univariate logistic regression between positive BT and smoking (OR = 4.6; P < 0.05) and abdominal pain (OR = 2.42; P < 0.05) (Table 1). Interestingly, multivariate analysis showed that this association remained strongly positive and that two additional factors associated with a positive BT have been identified, anemia (OR = 4.08; P < 0.05) and bloating (OR = 5.39; P < 0.05) (Table 2). No association was identified with gender, age, obesity, and risk factors for SIBO.

Type of antibiotic treatment for SIBO and its clinical response

Antibiotics were used in 43% of patients with a positive BT and 2.2% of patients with a negative BT (Fig. 1). The most commonly prescribed antibiotic in patients was metronidazole (Table 3). However, no difference was observed in symptom improvement in patients with or without antibiotic treatment.

Discussion

In this study, 46 out of 136 BT (LBT and/or BT) were compatible with SIBO (33.8%). A positive BT was strongly associated with the presence of abdominal pain, bloating, smoking, and anemia. Interestingly, there was no association with the chronic diseases known to be associated with SIBO (such as cirrhosis, scleroderma, celiac disease, chronic pancreatitis). Furthermore, among the 20 patients with a positive BT, only nine (45%) saw clinical improvement in gastrointestinal symptoms.

Our results demonstrate that the high occurrence of SIBO remains comparable to recently published studies on the prevalence of SIBO in patients with chronic pancreatitis [23-25], scleroderma [6], celiac disease [15, 26], and primary biliary cholangitis [16]. Although our study did not show a statistically significant association between SIBO and these pathologies, it should be sought in these patients because of its high prevalence.

Culture of jejunal aspirates has long been considered the gold standard in diagnosing SIBO, but it is not routinely available and is invasive. BTs, on the other hand, are more readily available, non-invasive and validated for the diagnosis of SIBO [21, 27]. Both the LBT and GBT have similar specificity and sensitivity, with the LBT being slightly more specific and GBT more sensitive [20, 27]. In order to increase both the sensitivity and specificity for the diagnosis of SIBO, we in-

### Table 1. Characteristics of Patients Who Completed a BT: Comparison Between the Two Groups SIBO⁻ and SIBO⁺

| Characteristics | SIBO⁻ | SIBO⁺ | OR    | P value |
|-----------------|-------|-------|-------|---------|
| Demographics    |       |       |       |         |
| Mean age (year), mean (range) | 50.49 (23 - 78) | 52.72 (20 - 80) | -      | 0.39    |
| BMI (kg/m²), mean (range) | 25.41 (14.53 - 52.47) | 24.88 (17.58 - 33.33) | -      | 0.71    |
| Women (n) | 63 % (57) | 63% (29) | -      | 0.97    |
| Habits |       |       |       |         |
| Smoking, % (n) | 31.3 (5) | 68.8 (11) | 4.6 (95% CI 1.45 - 15.06) | 0.01 |
| Alcohol, % (n) | 53.3 (8) | 46.7 (7) | 1.5 (95% CI 0.53 - 4.77) | 0.41 |
| Comorbidities   |       |       |       |         |
| Diabetes, % (n) | 64 (16) | 36 (9) | 1.0 (95% CI 0.53 - 4.77) | 0.87 |
| Chronic pancreatitis, % (n) | 61.5 (16) | 38.5 (10) | 1.2 (95% CI 0.52 - 3.09) | 0.60 |
| Chronic kidney disease, % (n) | 85.7 (6) | 14.3 (1) | 0.3 (95% CI 0.03 - 2.72) | 0.30 |
| Celiac disease, % (n) | 50 (2) | 50 (2) | 1.9 (95% CI 0.26-14.52) | 0.50 |
| Abdominal surgeries, % (n) | 70.4 (19) | 29.6 (8) | 0.7 (95% CI 0.30 - 1.93) | 0.58 |
| Scleroderma, % (n) | 71.4 (5) | 28.6 (2) | 0.7 (95% CI 0.13 - 3.99) | 0.73 |
| Cirrhosis, % (n) | 69.2 (18) | 30.8 (8) | 0.8 (95% CI 0.33 - 2.15) | 0.73 |
| PPI use, % (n) | 67.4 (29) | 32.6 (14) | 0.9 (95% CI 0.41 - 2.07) | 0.85 |
| Anemia, % (n) | 51.6 (16) | 48.4 (15) | 2.11 (95% CI 0.899 - 4.949) | 0.08 |
| Abdominal symptoms |       |       |       |         |
| Abdominal pain, % (n) | 57.9 (44) | 42.1 (32) | 2.42 (95% CI 1.101 - 5.340) | 0.02 |
| Bloating, % (n) | 72.1 (44) | 27.9 (17) | 1.58 (95% CI 0.746 - 3.337) | 0.23 |
| Diarrhea, % (n) | 60.8 (31) | 39.2 (20) | 1.43 (95% CI 0.679 - 2.988) | 0.34 |
| Constipation, % (n) | 61.9 (13) | 38.1 (8) | 1.27 (95% CI 0.480 - 3.336) | 0.63 |

BT: breath test; SIBO: small intestinal bacterial overgrowth; SIBO⁻: group without SIBO; SIBO⁺: group with SIBO; BMI: body mass index; PPIs: proton pump inhibitors; OR: odds ratio; CI: confidence interval. aChronic kidney disease (kidney damage or glomerular filtration rate < 60 mL/min/1.73 m² for at least 3 months); bHemoglobin < 140 g/L in men and < 120 g/L in women.
Predictors of SIBO in Patients Referred for BT

Table 2. Association Between Characteristics and SIBO+ After Multivariate Analysis

| Characteristics | OR  | P value |
|-----------------|-----|---------|
| Bloating        | 5.39| 0.01    |
| Abdominal pain  | 4.78| 0.01    |
| Anemia          | 4.08| 0.02    |
| Smoking         | 6.66| 0.01    |

Factors adjusted for in the multivariate analysis: age, gender, bloating, abdominal pain, constipation, diarrhea, weight loss, anemia, and smoking. SIBO: small intestinal bacterial overgrowth; SIBO+: group with SIBO; OR: odds ratio.

Table 3. Antibiotics Chosen for SIBO Treatment

| Antibiotics                              | n = 38 | %     |
|------------------------------------------|--------|-------|
| Metronidazole                            | 15     | 39.5% |
| Ciprofloxacin                            | 4      | 10.5% |
| Amoxicillin and clavulanate              | 4      | 10.5% |
| Amoxicillin                              | 3      | 7.9%  |
| Doxycycline                              | 5      | 13.2% |
| Rifaximin                                | 3      | 7.9%  |
| Tetracycline                             | 1      | 2.6%  |
| Minocycline                              | 1      | 2.6%  |
| Norfloxacin                              | 1      | 2.6%  |
| Trimethoprim-sulfamethoxazole            | 1      | 2.6%  |

SIBO: small intestinal bacterial overgrowth.

There is a controversy in the literature about the association between obesity and SIBO. Many factors such as intrinsic changes in intestinal motility, hypochlorhydria, the presence of intestinal diverticula, polypharmacy (with medications affecting gastrointestinal motility), and the higher prevalence of comorbidities in patients over 65 years old put them at higher risk of SIBO [3, 17]. Nevertheless, these same factors can be found also in the non-elderly population.

There is a controversy in the literature about the association between obesity and SIBO. Many factors such as intrinsic changes in intestinal motility, hypochlorhydria, the presence of intestinal diverticula, polypharmacy (with medications affecting gastrointestinal motility), and the higher prevalence of comorbidities in patients over 65 years old put them at higher risk of SIBO [3, 17]. Nevertheless, these same factors can be found also in the non-elderly population.

There is a controversy in the literature about the association between obesity and SIBO. Many factors such as intrinsic changes in intestinal motility, hypochlorhydria, the presence of intestinal diverticula, polypharmacy (with medications affecting gastrointestinal motility), and the higher prevalence of comorbidities in patients over 65 years old put them at higher risk of SIBO [3, 17]. Nevertheless, these same factors can be found also in the non-elderly population.

Figure 1. Antibiotic treatment. BT: breath test; SIBO: small intestinal bacterial overgrowth; SIBO+: group without SIBO; SIBO+: group with SIBO.

Clinical improvement after antibiotic treatment was similar in patients treated for SIBO compared to untreated patients. There was some heterogeneity of the antibiotics used, but metronidazole, ciprofloxacin, and amoxicillin and clavulanate were the most commonly chosen antibiotics to treat for SIBO.
Some patients had multiple courses of antibiotics for treatment of SIBO. In our sample, the clinical improvement in treated patients may be underestimated by the small number of patients included in both the treated and untreated subgroups with a positive BT. The small sample, as well as the retrospective nature of the study, unfortunately limits the power of our study to accurately determine clinical response to antibiotic treatment. Furthermore, the major disadvantage of a BT is that it does not identify the bacteria that cause the symptoms of SIBO, which makes the choice and duration of antibiotic treatment difficult [2]. Therefore, it is possible that patients did not have an adequate treatment adapted to their specific conditions. Only a few patients had rifaximin as a treatment for SIBO. Another point to consider is that the improvement was only judged by clinical parameters (abdominal pain, bloating, and diarrhea). A proportion of patients who reported not having any improvement could possibly have a negative BT after treatment. In that case, the lack of clinical response could simply be symptoms unrelated to SIBO. However, GBT positivity recurrence rate seems to be high despite appropriate antibiotic treatment and is associated with gastrointestinal symptoms relapse compatible with SIBO recurrence [36]. Finally, it is important to note that after their BT, all patients were referred to their physician who then decided whether or not treatment was clinically indicated. In fact, since the choice of antibiotic regimen was left to the discretion of the treating physician, there was no control over the treatment or not of our patients. Indeed, this could also explain our negative results concerning antibiotic treatment on SIBO symptoms.

This study demonstrates the experience of a tertiary center in neurogastroenterology and motility with a population at high risk for SIBO. However, it does include certain limitations including its retrospective nature, a study population specifically selected and referred to a single tertiary care center, the subjective assessment of clinical response after SIBO treatment, and the lack of randomization of treatment options (antibiotics versus no antibiotics).

Conclusions

In summary, we can conclude from our study that there is a high prevalence of SIBO in symptomatic patients who undergo breath testing. Abdominal pain, bloating, smoking, and anemia are strongly associated with the occurrence of SIBO in symptomatic patients referred for breath testing. Antibiotic treatment of SIBO needs to be further investigated to determine its efficacy on gastrointestinal symptoms and to better characterize the type of patients who would benefit from it.

Acknowledgments

None to declare.

Financial Disclosure

None to declare.

Conflict of Interest

None to declare.

Informed Consent

Not applicable.

Author Contributions

JLCK, RB, AT, SS and MB contributed to study concept and design; RB contributed to acquisition of data, analysis, interpretation of data and statistical analysis; JLCK drafted the manuscript; JLCK, RB, AT and MB were involved in critical revision of the manuscript for important intellectual content; MB was responsible for study supervision.

Data Availability

Any inquiries regarding supporting data availability of this study should be directed to the corresponding author.

Abbreviations

SIBO: small intestinal bacterial overgrowth; BT: breath test; LBT: lactulose breath test; GBT: glucose breath test; ppm: parts per million; SIBO+: groups of patients with SIBO; SIBO-: groups of patients without SIBO; OR: odds ratio; CFU: colony-forming units; ppm: part per million; BMI: body mass index; PPI: proton pump inhibitor; ANOVA: analysis of variance; NS: non-significant

References

1. Khoshini R, Dai SC, Lezcano S, Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci. 2008;53(6):1443-1454.
2. Gasbarrini A, Lauritano EC, Gabrielli M, Scarrellini E, Lupascu A, Ojetti V, Gasbarrini G. Small intestinal bacterial overgrowth: diagnosis and treatment. Dig Dis. 2007;25(3):237-240.
3. Bures J, Cyrany J, Kohoutova D, Forstl M, Rejchrt S, Kvetina J, Vorisek V, et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010;16(24):2978-2990.
4. Trespi E, Ferrieri A. Intestinal bacterial overgrowth during chronic pancreatitis. Curr Med Res Opin. 1999;15(1):47-52.
5. Lewis SJ, Franco S, Young G, O’Keefe SJ. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther. 1996;10(4):557-561.
6. Marie I, Ducrotte P, Denis P, Menard JF, Levesque H.
Small intestinal bacterial overgrowth in systemic sclerosis. Rheumatology (Oxford). 2009;48(10):1314-1319.

7. Reddyman SC, McCallum RW. Small intestinal bacterial overgrowth in gastroparesis: are there any predictors? J Clin Gastroenterol. 2010;44(1):e8-13.

8. Wedlake L, Thomas K, McGough C, Andreyev HJ. Small bowel bacterial overgrowth and lactose intolerance during radical pelvic radiotherapy: An observational study. Eur J Cancer. 2008;44(15):2212-2217.

9. Esposito I, de Leone A, Di Gregorio G, Giaquinto S, de Magistris L, Ferrieri A, Riegler G. Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol. 2007;13(45):6016-6021.

10. Posserud I, Stotzer PO, Bjornsson ES, Abrahamsson H, Simren M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56(5):802-808.

11. Klaus J, Spaniol U, Adler G, Mason RA, Reinschagen M, von Törpitz CC. Small intestinal bacterial overgrowth mimicking acute flare as a pitfall in patients with Crohn's Disease. BMC Gastroenterol. 2009;9:61.

12. Bauer TM, Steinbruckner B, Brinkmann FE, Ditzen AK, Schwacha H, Aponte JJ, Pelz K, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol. 2001;96(10):2962-2967.

13. Sabate JM, Jouet P, Harnois F, Meelhier C, Miska S, Grossin M, Coffin B. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg. 2008;18(4):371-377.

14. Pimentel M, Wallace D, Hallegua D, Chow E, Kong Y, Park S, Lin HC. A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. Ann Rheum Dis. 2004;63(4):450-452.

15. Rubio-Tapia A, Barton SH, Rosenblum AE, Murray JA. Prevalence of small intestine bacterial overgrowth and its clinical relevance to syndromes of intestinal bacterial overgrowth. J Clin Invest. 1971;50(5):1100-1107.

16. Liu Chen Kiow J, Vincent C, Sidani S, Bouin M. High occurrence of small intestinal bacterial overgrowth in primary biliary cholangitis. Neurogastroenterol Motil. 2019;31(11):e13691.

17. Gabrielli M, D'Angelo G, Di Rienzo T, Scarpellini E, Ojetti V. Diagnosis of small intestinal bacterial overgrowth in the clinical practice. Eur Rev Med Pharmacol Sci. 2013;17(Suppl 2):30-35.

18. Urita Y, Ishihara S, Akimoto T, Kato H, Hara N, Honda Y, Nagai Y, et al. Seventy-five gram glucose tolerance test to assess carbohydrate malabsorption and small bowel bacterial overgrowth. World J Gastroenterol. 2006;12(19):3092-3095.

19. Kerlin P, Wong L. Breath hydrogen testing in bacterial overgrowth of the small intestine. Gastroenterology. 1988;95(4):982-988.

20. Leung Ki EL, Roduit J, Delarive J, Guyot J, Michetti P, Dotta G. Small intestine bacterial overgrowth. Rev Med Suisse. 2010;6(233):186-188, 190-191.

21. Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S, Schmulson M, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American consensus. Am J Gastroenterol. 2017;112(5):775-784.

22. IBM Corp. Released 2016. IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY: IBM Corp.

23. Choung RS, Ruff KC, Malhotra A, Herrick L, Locke GR, 3rd, Harmsen WS, Zinsmeister AR, et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther. 2011;33(9):1059-1067.

24. Capurso G, Signoretti M, Archibugi L, Stigliano S, Delle Fave G. Systematic review and meta-analysis: Small intestinal bacterial overgrowth in chronic pancreatitis. United European Gastroenterol J. 2016;4(5):697-705.

25. Therrien A, Bouchard S, Sidani S, Bouin M. Prevalence of small intestinal bacterial overgrowth among chronic pancreatitis patients: a case-control study. Can J Gastroenterol Hepatol. 2016;2017:109431.

26. Losurdo G, Marra A, Shahini E, Girardi B, Giorgio F, Amoruso A, Pisani A, et al. Small intestinal bacterial overgrowth and celiac disease: A systematic review with pooled-data analysis. Neurogastroenterol Motil. 2017;29(6):e13028.

27. Gasbarrini A, Corazza GR, Gasbarrini G, Montalto M, Di Stefano M, Basilisco G, Parodi A, et al. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment Pharmacol Ther. 2009;29(Suppl 1):1-49.

28. Elphick DA, Chew TS, Higham SE, Bird N, Ahmad A, Sanders DS. Small bowel bacterial overgrowth in symptomatic older people: can it be diagnosed earlier? Gerontology. 2005;51(6):396-401.

29. Parlesak A, Klein B, Schecher K, Bode JC, Bode C. Prevalence of small bowel bacterial overgrowth and its association with nutrition intake in nonhospitalized older adults. J Am Geriatr Soc. 2003;51(6):768-773.

30. Newberry C, Tierney A, Pickett-Blakely O. Lactulose hydrogen breath test result is associated with age and gender. Biomed Res Int. 2016;2016:1064029.

31. Schatz RA, Zhang Q, Lodhia N, Shuster J, Toskes PP, Moshiree B. Predisposing factors for positive D-Xylose breath test for evaluation of small intestinal bacterial overgrowth: a retrospective study of 932 patients. World J Gastroenterol. 2015;21(15):4574-4582.

32. Giannella RA, Broitman SA, Zamcheck N. Vitamin B12 Deficiency and relation with spontaneous bacterial peritonitis. Ann Rheum Dis. 2004;63(4):450-452.

33. Harmes WS, Zinsmeister AR, et al. Small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol. 2007;13(45):6016-6021.

34. Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483-490.
35. Opstelten JL, Plassais J, van Mil SW, Achouri E, Pichaud M, Siersema PD, Oldenburg B, et al. Gut microbial diversity is reduced in smokers with Crohn's disease. Inflamm Bowel Dis. 2016;22(9):2070-2077.

36. Lauritano EC, Gabrielli M, Scarpellini E, Lupascu A, Novi M, Sottili S, Vitale G, et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol. 2008;103(8):2031-2035.